DE60228699D1 - Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil - Google Patents
Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracilInfo
- Publication number
- DE60228699D1 DE60228699D1 DE60228699T DE60228699T DE60228699D1 DE 60228699 D1 DE60228699 D1 DE 60228699D1 DE 60228699 T DE60228699 T DE 60228699T DE 60228699 T DE60228699 T DE 60228699T DE 60228699 D1 DE60228699 D1 DE 60228699D1
- Authority
- DE
- Germany
- Prior art keywords
- gemcitabin
- uracil
- fluoro
- preparations containing
- combination preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002949 fluorouracil Drugs 0.000 title abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
- 229960002930 sirolimus Drugs 0.000 title abstract 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 229960000235 temsirolimus Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28238501P | 2001-04-06 | 2001-04-06 | |
| US28238801P | 2001-04-06 | 2001-04-06 | |
| PCT/US2002/010912 WO2002080975A1 (en) | 2001-04-06 | 2002-04-05 | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60228699D1 true DE60228699D1 (de) | 2008-10-16 |
Family
ID=26961412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60228699T Expired - Fee Related DE60228699D1 (de) | 2001-04-06 | 2002-04-05 | Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1385551B1 (enExample) |
| JP (1) | JP2004525950A (enExample) |
| KR (1) | KR100862178B1 (enExample) |
| CN (1) | CN1309421C (enExample) |
| AT (1) | ATE406892T1 (enExample) |
| AU (1) | AU2007242958A1 (enExample) |
| BR (1) | BR0208627A (enExample) |
| CA (1) | CA2442849A1 (enExample) |
| DE (1) | DE60228699D1 (enExample) |
| EA (1) | EA010184B1 (enExample) |
| ES (1) | ES2312568T3 (enExample) |
| HU (1) | HUP0304093A3 (enExample) |
| IL (1) | IL157898A0 (enExample) |
| MX (1) | MXPA03009092A (enExample) |
| NO (1) | NO20034433L (enExample) |
| NZ (1) | NZ540047A (enExample) |
| PL (1) | PL363991A1 (enExample) |
| PT (1) | PT1385551E (enExample) |
| SG (1) | SG152906A1 (enExample) |
| SI (1) | SI1385551T1 (enExample) |
| WO (1) | WO2002080975A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| LT2762140T (lt) * | 2001-02-19 | 2017-06-26 | Novartis Ag | Solidinių smegenų navikų gydymas rapamicino dariniu |
| GB0124577D0 (en) * | 2001-10-12 | 2001-12-05 | Novartis Forschungsstiftung | Novel methods |
| BR0307544A (pt) | 2002-02-01 | 2004-12-07 | Ariad Gene Therapeutics Inc | Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
| EP1732583A4 (en) * | 2004-02-26 | 2009-08-12 | Penn State Res Found | COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS |
| WO2006027545A2 (en) * | 2004-09-10 | 2006-03-16 | Agency For Science, Technology And Research | Method |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| BRPI0618042A2 (pt) * | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| CN102579467A (zh) * | 2005-11-14 | 2012-07-18 | 阿里亚德医药股份有限公司 | 雷帕霉素衍生物在治疗癌症中的用途 |
| GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| EP2275103B1 (en) | 2005-11-21 | 2014-04-23 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
| CA2637069A1 (en) * | 2006-01-12 | 2007-07-19 | Novartis Ag | Combination of mtor inhibitor and antipolate compound |
| EP1880723A1 (en) * | 2006-07-14 | 2008-01-23 | Novartis AG | Combination of mTOR inhibitor and antifolate compound |
| WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| JP2009532503A (ja) * | 2006-04-05 | 2009-09-10 | ノバルティス アクチエンゲゼルシャフト | 癌を処置するための治療剤の組合せ |
| WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
| US20090311249A1 (en) * | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| WO2008016633A2 (en) * | 2006-08-02 | 2008-02-07 | Ariad Gene Therapeutics, Inc. | Combination therapy |
| KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| JP5919593B2 (ja) * | 2006-10-11 | 2016-05-18 | フージョン アンティボディーズ リミテッド | 併用療法 |
| CA2669415A1 (en) | 2006-11-14 | 2008-05-22 | Ariad Pharmaceuticals, Inc. | Solid dosage form comprising ap23573 |
| KR20090108086A (ko) | 2007-01-19 | 2009-10-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 췌장암 치료용 조성물 |
| EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| LT2481402T (lt) * | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| IL264349B2 (en) | 2009-04-06 | 2024-01-01 | Wyeth Llc | Regimen comprising neratinib for the treatment of cancer |
| BR112012003592B8 (pt) | 2009-08-19 | 2021-05-25 | Eisai R&D Man Co Ltd | composição farmacêutica contendo derivado de quinolina |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| EP2700403B1 (en) | 2011-04-18 | 2015-11-25 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| CA2957005C (en) | 2014-08-28 | 2021-10-12 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| SG11201706630UA (en) | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| CN114456176B (zh) | 2016-03-28 | 2024-08-30 | 因赛特公司 | 作为tam抑制剂的吡咯并三嗪化合物 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| KR102739325B1 (ko) | 2017-09-27 | 2024-12-09 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
| US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
| PH12022552347A1 (en) | 2020-03-06 | 2024-01-29 | Incyte Corp | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| JP4352115B2 (ja) * | 1997-01-24 | 2009-10-28 | クラヴィス・ファルマ・アーエスアー | ゲムシタビン誘導体 |
| TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
-
2002
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en not_active Ceased
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active Expired - Fee Related
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 EP EP02726710A patent/EP1385551B1/en not_active Expired - Lifetime
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
-
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
-
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PL363991A1 (en) | 2004-11-29 |
| EA200301091A1 (ru) | 2004-02-26 |
| NZ540047A (en) | 2007-01-26 |
| HK1060062A1 (en) | 2004-07-30 |
| CA2442849A1 (en) | 2002-10-17 |
| ES2312568T3 (es) | 2009-03-01 |
| NO20034433D0 (no) | 2003-10-03 |
| HUP0304093A2 (hu) | 2004-04-28 |
| CN1545419A (zh) | 2004-11-10 |
| JP2004525950A (ja) | 2004-08-26 |
| KR100862178B1 (ko) | 2008-10-09 |
| NO20034433L (no) | 2003-11-25 |
| SI1385551T1 (sl) | 2008-12-31 |
| KR20040007491A (ko) | 2004-01-24 |
| AU2007242958A1 (en) | 2008-01-10 |
| EA010184B1 (ru) | 2008-06-30 |
| SG152906A1 (en) | 2009-06-29 |
| IL157898A0 (en) | 2004-03-28 |
| WO2002080975A1 (en) | 2002-10-17 |
| BR0208627A (pt) | 2004-03-09 |
| HUP0304093A3 (en) | 2008-08-28 |
| MXPA03009092A (es) | 2004-02-12 |
| ATE406892T1 (de) | 2008-09-15 |
| EP1385551A1 (en) | 2004-02-04 |
| PT1385551E (pt) | 2008-11-03 |
| EP1385551B1 (en) | 2008-09-03 |
| CN1309421C (zh) | 2007-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406892T1 (de) | Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil | |
| BR0211769A (pt) | Combinações antineoplásicas | |
| NO20054133L (no) | Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor | |
| DE60226666D1 (de) | Wälz- und Gleitlagerbauteil und Wälzlager | |
| ATE414514T1 (de) | Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend | |
| SG148031A1 (en) | Use of cci-779 as an antineoplastic agent | |
| CY2008014I2 (el) | Β-αμινο-τετραϋδροϊμιδαζο-(1,2-α)-πυραζινες και τετραϋδροτριαζολο-(4,3-α)-πυραζινες ως αναστολεις της διπεπτιδυλο πεπτιδασης για την αγωγη ή προληψη του διαβητη | |
| CY1109119T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη | |
| MXPA03010085A (es) | Composiciones y su uso en la hiperplasia. | |
| DE60328677D1 (de) | Stent und stent-prothese | |
| FR2840523B1 (fr) | Article multicouche absorbant et recurant | |
| NO20024099D0 (no) | Lavdose entecavir-formulering og anvendelse | |
| BRPI0508451A (pt) | método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica | |
| DE60334592D1 (de) | Differentialpumpvorrichtung und Belichtungsgerät | |
| ECSP056114A (es) | Combinaciones antineoplásicas | |
| PT1228028E (pt) | Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular | |
| EP1476419A4 (en) | N-BIPHENYLMETHYLAMINOCYCLOALKANCARBOXAMID-DERIVATIVE | |
| FR2849769B1 (fr) | Implant et prothese articulaire le comprenant | |
| AR033012A1 (es) | Combinaciones antineoplasicas | |
| BR0208566B1 (pt) | Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica | |
| CL2004000877A1 (es) | Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu | |
| ITVR20010031A0 (it) | Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative. | |
| EP1578348A4 (en) | PREPARATION CONTAINING BIOACTIVE AGENTS AND METHOD OF USE | |
| ITTO20040760A1 (it) | Uso di un corticosteroide in associazione ad altri principi attivi per il trattamento della stenosi vascolare e la prevenzione della restenosi vascolare | |
| ITRM20020119A1 (it) | Composizioni contenenti plgf ad uso farmaceutico e cosmetico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |